Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

Courts Rule On J&J Investor Class, Abortion Rights And More No Photo Available

Gianna Ferrarin

Law360 Healthcare Authority looks at the U.S. Supreme Court's rejection of a petition by Johnson & Johnson challenging the certificati... (more story)

3 Key Takeaways From The RFK Jr. Hearings No Photo Available

Yeji Jesse Lee

Experts told Law360 that Health and Human Services Secretary Robert F. Kennedy Jr. appears to be avoiding “politically unsavory” issue... (more story)

Medical Ethics Researchers Talk Doc Misconduct Trends No Photo Available

Mark Payne

Law360 Healthcare Authority talks to Western Michigan University researchers about misconduct trends in healthcare professions and wha... (more story)